It is therefore important to look at how to bridge these gaps across disciplines..
Standardised solutions lend themselves to efficiencies in construction and the application of DfMA.Operational benefits.
Standardised solutions facilitate efficient operation and maintenance, as well as aiding staff and prisoner wayfinding and navigation.. A developmental process, an evidence-based approach.Bryden Wood had been working with MoJ since 2011, when we helped developed their BIM Implementation Plan.We went on to join the MoJ’s multi-disciplinary designer framework in 2014 and, before PETP, developed a ‘proof of concept’ for the application of DfMA to the custodial estate..
In February 2016, at the beginning of PETP, we conducted research into the aspects of design that can help influence rehabilitative outcomes.The huge stakeholder engagement effort that informed the new prison design was the biggest piece of research ever undertaken by the department into the effectiveness of prison design and building use.
This is a very good example of how evidence underpins our approach to design.. Stakeholders and sources of evidence included:.
Serving and former prison governors, staff and prisoners.This is thanks to the whole project team's successful delivery of a large and complex project ahead of schedule and under budget during a global pandemic.. GSK Parma Attachment Inhibitor: meeting a life-saving need.
Aiming to introduce manufacturing capability into GSK’s Parma site for Fostemsavir (a life-saving HIV drug for patients with limited or no other treatment options available), this project’s brief was ambitious.. To maintain supply while the drug was in development and clinical trials, GSK had to build and commission a brand new facility in a shorter timeframe than had ever been achieved before.. As lead designer, Bryden Wood formed a collaborative team with external partners and client representatives to capture functional requirements in “Chip” models that could be rapidly configured to allow many design options to be evaluated in a short time..The ability to undertake rapid digital optioneering was particularly important as forecast demand volumes were uncertain and clinical manufacturing requirements for the drug were still being developed during the design phase.
We developed a capacity model in-house to inform decisions around unit operations and scale..The final design concept was deliberately simple.
(Editor: Best Kettles)